Chondroitin Sulfate

This is a strong recommendation resting on an absence of benefit rather than on demonstrated harm, and the guideline notes glucosamine's toxicity is low. It hardened from a conditional recommendation against glucosamine in 2012, so a reader may still meet the older advice. The search closed in 2018.

None was designed to detect rare harm, and the participants were people with knee osteoarthritis, not the general population. The chondroitin review's finding of fewer serious events on treatment than on placebo more likely reflects sparse, inconsistently reported data than a real effect.

The 0.9 cm threshold is these authors' own choice rather than an agreed one, and a reader accepting a smaller threshold would read some of these intervals differently. Restricting by trial size excludes most of the older positive literature, so this is not the body of trials other reviews pool.

A placebo response of six in ten leaves very little room for a supplement to show a difference, and every arm could take up to 4,000 mg of paracetamol a day as rescue, narrowing the gaps further. The trial used glucosamine hydrochloride, not the sulfate salt sold in Europe as a medicine.

This is a continuation in the participants who met stricter X-ray criteria, not a fresh randomisation, so it carries the parent trial's high placebo response with it. Two years of dropout leaves less power, not more. The authors call the trends beneficial but not significant, which describes a null.

The result is fragile: its interval reaches to 0.002 mm, its p value is 0.046, and it survives only after adjustment for sex, weight and baseline severity. It is one of several comparisons, so a multiple-testing correction would likely remove it. Whether a tenth of a millimetre is felt is untested.

Milder knees showed a trend toward benefit with no significance test attached to it, so it is not a result and should not be reported as one. The trial used glucosamine hydrochloride rather than the sulfate salt, which is one of the two ways it differs from the three-year trials reporting a benefit.

This is one manufacturer's label, so its choices are evidence about this product rather than about US labelling rules in general. The document also disagrees with itself: the index title says tablet where the Drug Facts panel and carton say capsule, and three different effective dates appear in it.

The 10-percentage-point figure usually quoted from it is the one it rates low quality, with high bias risk and heavy disagreement. The benefit became uncertain whenever the analysis narrowed to trials that concealed allocation properly, to large trials, or to independently funded ones.

Chondroitin's knee-pain benefit is small, and whether it is worth having is unsettled. The largest trials put it below the smallest change a patient would notice, while Cochrane counts six people in a hundred helped.

This review does not separate trials by manufacturer, by funder, or by how well allocation was concealed, the three things earlier analyses of this literature found decide the answer. Its combination conclusion rests on three trials. It reports direction and significance, no effect sizes.

Whether chondroitin and glucosamine ease pain turns on method, not data. Analyses splitting trials by funder, brand and trial quality find no difference a patient would notice; the review finding a benefit did not split them.